Outcomes of SARS-CoV-2 infection among lung transplant recipients: A single center retrospective study.
Details
Serval ID
serval:BIB_B46C384138BD
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Outcomes of SARS-CoV-2 infection among lung transplant recipients: A single center retrospective study.
Journal
Transplant infectious disease
ISSN
1399-3062 (Electronic)
ISSN-L
1398-2273
Publication state
Published
Issued date
02/2023
Peer-reviewed
Oui
Volume
25
Number
1
Pages
e14007
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
Lung transplant recipients (LTRs) are at increased risk for coronavirus disease 2019 (COVID-19)-associated complications.
We aimed to describe the outcomes of polymerase chain reaction-documented severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in LTRs followed at our institution from March 2020 to July 2022. The primary outcome investigated was hospitalization or death from COVID-19-related symptoms within 28 days from diagnosis.
Overall, 60 cases were included, of which 18 (30%) reached the primary outcome. Only one patient (2%) died. Anti-spike monoclonal antibodies (mAbs) were administered as early treatment in 36 patients (casirivimab/imdevimab = 2, sotrovimab = 31, and tixagevimab/cilgavimab = 3). Multivariate analysis revealed that age >60 years (p = .003; odds ratio [OR] 9.41; confidence interval [CI] 2.52-41.05) was associated with a higher risk for the primary outcome, while administration of mAbs as early treatment (p = .030; OR 0.23; CI 0.06-0.87) was associated with a lower risk. No effect of vaccination and SARS-CoV-2 variant was observed. Forced expiratory volume in 1 s and forced vital capacity values did not decrease among 37 patients who had spirometry performed 1 month after COVID-19.
We observed a relatively low morbidity and mortality of COVID-19 in LTR. mAb administration was associated with a better outcome.
We aimed to describe the outcomes of polymerase chain reaction-documented severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in LTRs followed at our institution from March 2020 to July 2022. The primary outcome investigated was hospitalization or death from COVID-19-related symptoms within 28 days from diagnosis.
Overall, 60 cases were included, of which 18 (30%) reached the primary outcome. Only one patient (2%) died. Anti-spike monoclonal antibodies (mAbs) were administered as early treatment in 36 patients (casirivimab/imdevimab = 2, sotrovimab = 31, and tixagevimab/cilgavimab = 3). Multivariate analysis revealed that age >60 years (p = .003; odds ratio [OR] 9.41; confidence interval [CI] 2.52-41.05) was associated with a higher risk for the primary outcome, while administration of mAbs as early treatment (p = .030; OR 0.23; CI 0.06-0.87) was associated with a lower risk. No effect of vaccination and SARS-CoV-2 variant was observed. Forced expiratory volume in 1 s and forced vital capacity values did not decrease among 37 patients who had spirometry performed 1 month after COVID-19.
We observed a relatively low morbidity and mortality of COVID-19 in LTR. mAb administration was associated with a better outcome.
Keywords
Humans, Middle Aged, COVID-19, SARS-CoV-2, Retrospective Studies, Transplant Recipients, Lung, casirivimab/imdevimab, lung transplantation, omicron variant, sotrovimab, vaccination
Pubmed
Web of science
Create date
17/01/2023 15:28
Last modification date
28/02/2023 6:51
Usage data
